Tizanidine — Side Effects, Overdose and Dangerous Drop in Blood Pressure

EFFECTIVE | TOXIC

What Names Tizanidine Is Sold Under

The international nonproprietary name is tizanidine; the Latin variants are Tizanidine and Tizanidinum. Medicinal products usually contain tizanidine hydrochloride — Tizanidine hydrochloride — with the dosage expressed in terms of tizanidine. The main dosage forms are tablets and capsules for oral administration; liquid oral formulations are registered in some markets. Common trade names include Sirdalud, Zanaflex, Tizalud, Tizanil, Tizanidine-Teva, Tizagelan, and other regional generics. In some markets, combination products or co-packaged medicines are available that contain tizanidine together with paracetamol, diclofenac, aceclofenac, or other analgesics. Therefore, it is important to check not only the name on the package but also the “active ingredient” line: taking Sirdalud, Tizalud, and a product called “Tizanidine” at the same time means duplicating the same dose.

Why Tizanidine Is Considered Harmless and Where the Real Risk Begins

Tizanidine is often perceived as an ordinary tablet “for a stiff back,” even though a therapeutic dose can cause pronounced drowsiness, muscle weakness, orthostatic hypotension, bradycardia, and fainting. A person may attribute sudden weakness, unsteadiness, darkening of vision, or a fall to fatigue, dehydration, or the underlying disease without recognizing a drug-related reaction. The risk increases especially after a repeat dose, when combined with alcohol, antihypertensive or sedative medications, and when different brands of tizanidine are accidentally taken together. In a single-dose study, hypotension occurred in 16% of patients after 8 mg and in 33% after 16 mg, while drowsiness occurred in 78% and 92%, respectively. This dose-dependent effect leaves no basis for considering the drug a neutral “muscle relaxer.”

Side Effects During the First Hours and Days of Treatment

Common reactions to tizanidine include dry mouth, drowsiness, slowed responsiveness, asthenia, dizziness, and reduced ability to function. They may occur after the first dose and become more pronounced as the dose is increased. Clinically significant complications include orthostatic hypotension, slowing of the pulse, impaired coordination, blurred vision, speech disturbances, nausea, vomiting, constipation, and excessive reduction in muscle tone, which can cause the patient to lose stability and fall. Visual hallucinations and delusional experiences are possible: in controlled studies, such reactions were recorded in 5 of 170 patients, and in one patient psychotic symptoms persisted for at least two weeks after discontinuation. Life-threatening reactions include a profound drop in blood pressure with fainting, severe bradycardia, depression of consciousness and respiration, anaphylaxis, and angioedema of the tongue or larynx.

Consequences of Long-Term or Repeated Use

With long-term treatment, the main risk is not classic irreversible cumulative nephrotoxicity, but dose-dependent central nervous system depression, recurrent episodes of hypotension, falls, impaired liver function, and the development of physiological dependence on the α₂-adrenergic effect. Tizanidine can cause elevated transaminase activity, hepatocellular injury, hepatitis, and clinically significant hepatotoxicity. Liver test results usually return to normal after the drug is discontinued, but continuing treatment in the presence of jaundice, dark urine, nausea, anorexia, or rising ALT increases the likelihood of severe liver injury. After several weeks of high-dose use, abrupt cessation of sympathetic suppression can trigger a rebound hyperadrenergic reaction: arterial hypertension, tachycardia, tremor, anxiety, and worsening muscle hypertonia. The absence of pronounced side effects during the first few days does not rule out subsequent liver injury or withdrawal syndrome.

Contraindications and High-Risk Groups

Tizanidine is contraindicated when used concurrently with potent CYP1A2 inhibitors, primarily ciprofloxacin and fluvoxamine, and in patients with known hypersensitivity to the drug. Use is contraindicated in severe hepatic impairment because tizanidine is almost completely metabolized by the liver and its concentration may rise unpredictably. When creatinine clearance is below 25 mL/min, elimination is reduced by more than half, prolonging drowsiness, weakness, and hypotension. Older patients are particularly vulnerable because of slower clearance and a high risk of falls. In patients with pre-existing low blood pressure, bradycardia, antihypertensive therapy, dehydration, or cardiac conduction disorders, even a small dose may cause clinically significant hemodynamic deterioration. Safety in children has not been established; data during pregnancy and breastfeeding are insufficient. A particular danger exists for patients in whom increased muscle tone helps maintain posture, standing, or walking: excessive muscle relaxation can worsen rather than improve their functional ability.

Dangerous Drug Interactions

The combination of tizanidine with ciprofloxacin is contraindicated: in a controlled study, the antibiotic increased the area under the pharmacokinetic curve of tizanidine by an average of 10-fold and the maximum concentration by 7-fold, sharply intensifying hypotension and drowsiness. Fluvoxamine increased systemic exposure to tizanidine by an average of 33-fold and, in some participants, by more than 100-fold; systolic blood pressure fell to 80 mmHg or lower. Other CYP1A2 inhibitors are also highly undesirable: certain fluoroquinolones, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, zileuton, acyclovir, and ticlopidine. Combined oral contraceptives containing ethinylestradiol and gestodene increased tizanidine AUC almost fourfold. Alcohol increases systemic exposure to the drug and adds to central nervous system depression. Opioids, benzodiazepines, hypnotics, tricyclic antidepressants, baclofen, and other muscle relaxants increase drowsiness, impaired coordination, and the risk of respiratory depression. Antihypertensive agents, clonidine, guanfacine, and other α₂-agonists intensify the drop in blood pressure and bradycardia. Smoking accelerates tizanidine metabolism; therefore, abruptly stopping smoking could theoretically increase its concentration — this is not an argument for continuing to smoke, but a reason to reassess the dose. Tablets and capsules should not be interchanged without medical guidance or alternated between fasting and post-meal administration: changes in dosage form and food intake alter bioavailability.

Typical Patient Errors

The most dangerous mistake is taking tizanidine as a universal painkiller for any type of back pain, although the drug does not eliminate nerve root compression, inflammation, injury, infection, or structural disease of the spine. If rapid relaxation does not occur, the patient may repeat the tablet too soon, increase the single dose, or add Sirdalud to a tizanidine generic already taken. Other common mistakes include drinking alcohol “to enhance relaxation,” taking the drug together with a sleeping pill or opioid, continuing to drive while drowsy, using someone else’s prescription, and ignoring sudden weakness, a slow pulse, or darkening of vision. It is dangerous not to inform the physician about starting treatment with ciprofloxacin, fluvoxamine, or combined contraceptives. Tablets and capsules should not be alternated arbitrarily, the relationship between dosing and meals should not be changed, a missed dose should not be doubled, and a long-term course should not be stopped abruptly. The absence of complications after several tablets does not prove that the next dose will be safe: tizanidine concentrations vary severalfold among patients and can change sharply under the influence of concomitant medications.

Tizanidine Overdose and Poisoning

There is no single established toxic dose of tizanidine. The maximum recommended daily dose is 36 mg, while the official prescribing information warns of an increased risk of adverse reactions with a single dose greater than 8 mg. In a series of 45 isolated poisonings, the mean ingested dose was 72 mg. The lowest dose associated with pronounced hypotension in an adult was 28 mg; coma was observed after an estimated ingestion of 60–120 mg. In a two-year-old child, 16 mg caused bradycardia and drowsiness. These figures must not be used as a “safe threshold”: 4 mg may become dangerous when combined with ciprofloxacin or fluvoxamine, as well as in renal or hepatic impairment, low baseline blood pressure, or concurrent use of hypotensive or sedative medications.

The first symptoms usually develop within the first few hours: pronounced drowsiness, slowed responsiveness, weakness, dizziness, dry mouth, and constricted pupils. Confusion, agitation, vomiting, bradycardia, a drop in blood pressure, cardiac conduction disturbances, respiratory depression, and coma may then occur. In most observations, the main manifestations lasted less than 12 hours, but severe cases required intubation, intravenous fluids, and vasopressors, while hemodynamic instability persisted for up to 24 hours or longer. There is no specific antidote. Naloxone has occasionally been associated with a brief improvement in consciousness, but it was ineffective in most reported cases and is not considered a reliable antidote. If overdose is suspected, loss of consciousness should not be awaited: urgent toxicological care and monitoring of respiration, blood pressure, pulse, and ECG are necessary.

A Safe Integrative Alternative to Tizanidine

In chronic spastic-dystonic, hypomyelinating, and neurodegenerative conditions, a proprietary neurorehabilitation mixture based on standardized plant extracts may be considered as an alternative to long-term symptomatic suppression of muscle tone. Its composition, component ratios, and manufacturing technology are not disclosed. The mixture is prepared individually by a clinical pharmacologist upon a request submitted through the treating specialist, after assessment of the diagnosis, severity of motor impairment, concomitant therapy, and potential interactions.

The mixture does not reproduce the central α₂-adrenergic action of tizanidine and is not intended for the emergency suppression of severe spasticity. Its pharmacological direction includes reducing neuroinflammation and oxidative injury and supporting microcirculation, neuroplasticity, axonal metabolism, myelination, and restorative processes in nervous tissue. Therefore, the effect develops gradually and is assessed not by immediate muscle relaxation but by changes in muscle tone, motor function, pain, coordination, and tolerance of rehabilitation.

Use of the mixture is most justified in Strümpell disease and other hereditary spastic paraplegias, Pelizaeus–Merzbacher disease, PKAN, and dyskinetic and mixed spastic-dystonic forms of cerebral palsy. In the ataxic form of cerebral palsy, spinal muscular atrophy, and neurological manifestations of Kabuki syndrome, it may be considered as supportive neurometabolic and restorative therapy rather than as a means of directly reducing muscle tone.

Complete replacement of tizanidine is primarily possible in a stable condition, with moderate spasticity or a painful muscular-tonic syndrome, when rapid central muscle-relaxant action is not required. In severe spasticity, frequent nocturnal spasms, pronounced clonus, or the risk of contractures, falls, or loss of the ability to perform self-care, the mixture is used as an adjunct. Reduction or discontinuation of tizanidine is carried out gradually and only by decision of the treating specialist together with a clinical pharmacologist.

When myofascial, vertebrogenic, or radicular pain predominates, Chonsal may additionally be considered. In the consequences of stroke, cerebrovascular insufficiency, and impaired microcirculation, Gingkobonin, Jangsaeng, and Angunsahyang may have an adjunctive role. These products are not direct analogues of tizanidine and are selected according to the predominant pathological mechanism.

The Real Effectiveness of Tizanidine and Medical Errors

Tizanidine does reduce central spasticity in multiple sclerosis, spinal cord injuries and diseases, hereditary spastic syndromes, and certain post-stroke conditions. It reduces resistance to passive movement and the severity of hyperreflexia, painful spasms, and clonus. Its effect usually develops relatively quickly but lasts for a limited period and does not eliminate the cause of damage to the motor pathways.

The drug does not restore myelin, slow neurodegeneration, correct a genetic defect, or restore normal function to damaged neurons. Reduced muscle tone also does not always mean improved walking or independence. In some patients, spasticity partially supports an upright position and the ability to transfer and stand. Excessive muscle relaxation may impair function more severely than the original hypertonia.

A common medical error is prescribing tizanidine for any back pain without a confirmed muscular-tonic component. Other errors include increasing the dose too quickly, continuing treatment despite pronounced weakness and drowsiness, ignoring low blood pressure or liver and kidney disease, failing to check for interactions, and prescribing the drug without a subsequent discontinuation plan. If a patient becomes lethargic and unstable and can no longer walk normally, this should not automatically be regarded as successful treatment of spasticity.

Safety Monitoring During Treatment

Before starting treatment, blood pressure, pulse rate, the presence of orthostatic dizziness or fainting episodes, and liver and kidney function should be assessed. After treatment begins and after each dose increase, blood pressure, pulse, severity of drowsiness, walking stability, muscle strength, and the ability to perform habitual movements are monitored. In patients with dizziness, blood pressure should be measured not only at rest but also after standing upright.

ALT and AST levels are measured before long-term treatment and repeated after a stable therapeutic dose has been reached. Repeat monitoring is required in cases of nausea, loss of appetite, unusual weakness, pain or heaviness in the right upper abdomen, dark urine, pale stools, or jaundice. A significant increase in transaminases or the appearance of clinical signs of liver injury requires discontinuation of tizanidine and further evaluation.

Immediate medical assistance is required in cases of fainting, pronounced slowing of the pulse, a sharp drop in blood pressure, impaired consciousness, inability to wake the patient, respiratory depression, swelling of the tongue or larynx, a generalized skin reaction, hallucinations, seizures, or jaundice. Waiting is dangerous because of the risk of injury from falling, respiratory failure, severe hypotension, and progression of drug-induced liver injury.

Proper Discontinuation of Tizanidine

After a single or short-term use of a small dose, prolonged dose reduction is usually not required. After a regular course, especially when high doses have been used, treatment has been prolonged, or tizanidine has been combined with opioid medications, it should not be discontinued abruptly. Rebound increases in blood pressure, tachycardia, anxiety, tremor, headache, and a sudden increase in muscle tone may occur.

The dose is reduced gradually while monitoring blood pressure, pulse, frequency of spasms, severity of clonus, and the patient’s functional abilities. The rate of withdrawal is selected individually. If hypertension, tachycardia, or a sharp increase in spasticity occurs, dose reduction is slowed and the treatment regimen is reassessed.

Starting the neurorehabilitation mixture does not eliminate the need for gradual withdrawal of tizanidine. The plant-based formula cannot immediately counteract the α₂-adrenergic rebound reaction. It is introduced as a separate stage of therapy so that tolerability can be assessed and the effects of the mixture can be distinguished from the consequences of reducing the dose of the synthetic drug.

A Rational Approach to Treatment

Tizanidine is justified when it is necessary to rapidly reduce pronounced central spasticity, painful spasms, or clonus that interfere with sleep, care, and physical rehabilitation. It should be used at the minimum dose that provides genuine functional benefit rather than maximum muscle relaxation at any cost.

In a stable chronic condition, when long-term support of nervous tissue, microcirculation, neuroplasticity, and myelination is required, preference may be given to an individually prepared neurorehabilitation mixture. In moderate muscular-tonic syndrome, it may become the primary treatment after gradual discontinuation of tizanidine. In severe central spasticity, it is more rational to combine limited use of tizanidine with long-term integrative support, therapeutic exercise, orthotic management, and rehabilitation.

The goal of the integrative approach is not to abandon an effective synthetic drug when it is genuinely needed, but to reduce sedation, hypotension, drug interactions, liver burden, and the risk of withdrawal syndrome. The neurorehabilitation mixture is prepared individually by a clinical pharmacologist only upon a request submitted through the treating specialist; independently obtaining the formulation, preparing it, or replacing the prescribed treatment is unacceptable.

If you have questions about the subject of this article, you can ask a clinical pharmacologist in the comments or schedule an appointment using the link: https://asiabiopharm.com/konsultaciii/